Eli Lilly Discloses 19.9% Stake in TRex Bio Post-IPO, Flags Strategic Discussions
TRXB is trading near its 52-week low of $13.21 (9.5% above the low) on light trading volume (0.2× avg).
Summary
Eli Lilly disclosed a 19.9% stake in TRex Bio after the IPO, including 875,000 shares bought at $14.00, and said it may discuss strategic initiatives with management and the board.
Key Events · Ownership and Investor Activity · TRXB
-
Eli Lilly Reports 19.9% Stake
Lilly beneficially owns 5,480,872 shares, or 19.9% of the 27,577,535 shares outstanding as of October 13, 2026, making it the largest disclosed holder.
-
Stake Built From Conversions and IPO
2,510,411 shares came from Series A preferred conversion and 2,095,461 from Series B conversion; Lilly also bought 875,000 IPO shares at $14.00 for about $12.3 million in cash on hand.
-
Lilly Flags Strategic Discussions
The filing states Lilly expects to engage with directors, officers, management and other parties on operational, financial and strategic initiatives and may evaluate any matter under Items 4(a)-(j).
-
Board Seat and Registration Rights
Lilly employee Julie Gilmore sits on the TRex Bio board, and Lilly holds demand, piggyback and shelf registration rights under the Investors' Rights Agreement.
Analysis · TRXB · Life Sciences
Eli Lilly reported beneficial ownership of 5,480,872 TRex Bio shares, or 19.9% of the 27,577,535 shares outstanding as of October 13, 2026. That stake was built from 2,510,411 Series A preferred shares and 2,095,461 Series B preferred shares that converted at the IPO, plus 875,000 shares bought in the IPO at $14.00 for roughly $12.3 million. By a wide margin, this makes Lilly the company's largest disclosed holder, far ahead of the 7.0% SV Biotech position reported the same day. The filing is not a passive placeholder: Lilly states it expects to engage with directors, officers, management and other parties on operational, financial and strategic initiatives and may evaluate any matter under Items 4(a)-(j), while noting its employee Julie Gilmore already sits on the TRex Bio board. Lilly also holds registration rights under the Investors' Rights Agreement and is subject to a 180-day lock-up running from October 8, 2026, so no near-term selling pressure is implied. The combination of a 19.9% strategic holder, board representation and explicit discussion language gives Lilly substantial influence over TRex Bio's direction.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.5% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRXB was trading at $14.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $384.5M. The 52-week trading range was $13.21 to $15.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.